Venus Remedies Limited (BOM:526953)
India · Delayed Price · Currency is INR 1,859.35
-28.30 (-1.50%)
At close: Jun 16, 2026
Venus Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 7,696 | 6,479 | 6,014 | 5,555 | 6,002 |
| 7,696 | 6,479 | 6,014 | 5,555 | 6,002 | |
Revenue Growth (YoY) | 18.79% | 7.72% | 8.27% | -7.44% | 9.50% |
Cost of Revenue | 3,873 | 3,801 | 3,564 | 3,329 | 3,870 |
Gross Profit | 3,823 | 2,678 | 2,451 | 2,226 | 2,132 |
Selling, General & Admin | 2,169 | 1,862 | 1,697 | 1,397 | 1,281 |
Research & Development | 181.7 | 180.85 | 158.4 | 228.85 | 230.3 |
Other Operating Expenses | - | -89.82 | -5.08 | -4.86 | -4.63 |
Operating Expenses | 2,607 | 2,178 | 2,114 | 1,944 | 1,842 |
Operating Income | 1,216 | 500.05 | 336.65 | 282.13 | 290.43 |
Interest Expense | -0.4 | -0.65 | -0.94 | -1.18 | -3.03 |
Interest & Investment Income | - | 45.42 | 41.66 | 18.99 | 8.16 |
Currency Exchange Gain (Loss) | - | 50.07 | 59.54 | 73.24 | 64.15 |
Other Non Operating Income (Expenses) | 125.8 | 7.97 | 4.01 | 6.04 | 4.37 |
EBT Excluding Unusual Items | 1,342 | 602.85 | 440.92 | 379.22 | 364.08 |
Gain (Loss) on Sale of Investments | - | 16.28 | 5.51 | 0.08 | - |
Other Unusual Items | - | 99.13 | - | - | - |
Pretax Income | 1,342 | 718.27 | 446.43 | 379.3 | 364.08 |
Income Tax Expense | 313.7 | 265.12 | 161.53 | 113.65 | -43.16 |
Net Income | 1,028 | 453.15 | 284.91 | 265.66 | 407.24 |
Net Income to Common | 1,028 | 453.15 | 284.91 | 265.66 | 407.24 |
Net Income Growth | 126.81% | 59.05% | 7.25% | -34.77% | -34.07% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 |
Shares Change (YoY) | 0.00% | - | - | 1.30% | 6.92% |
EPS (Basic) | 76.89 | 33.90 | 21.31 | 19.87 | 30.86 |
EPS (Diluted) | 76.89 | 33.90 | 21.31 | 19.87 | 30.86 |
EPS Growth | 126.81% | 59.08% | 7.22% | -35.60% | -38.33% |
Free Cash Flow | 1,181 | 768.15 | 279.67 | 288.09 | 273.94 |
Free Cash Flow Per Share | 88.37 | 57.47 | 20.92 | 21.55 | 20.76 |
Dividend Per Share | 10.000 | - | - | - | - |
Gross Margin | 49.68% | 41.34% | 40.75% | 40.07% | 35.52% |
Operating Margin | 15.80% | 7.72% | 5.60% | 5.08% | 4.84% |
Profit Margin | 13.36% | 6.99% | 4.74% | 4.78% | 6.78% |
Free Cash Flow Margin | 15.35% | 11.86% | 4.65% | 5.19% | 4.56% |
EBITDA | 1,473 | 696.01 | 601.08 | 605.1 | 625.77 |
EBITDA Margin | 19.14% | 10.74% | 9.99% | 10.89% | 10.43% |
D&A For EBITDA | 256.7 | 195.96 | 264.43 | 322.98 | 335.34 |
EBIT | 1,216 | 500.05 | 336.65 | 282.13 | 290.43 |
EBIT Margin | 15.80% | 7.72% | 5.60% | 5.08% | 4.84% |
Effective Tax Rate | 23.38% | 36.91% | 36.18% | 29.96% | - |
Revenue as Reported | 7,822 | 6,688 | 6,130 | 5,658 | 6,085 |
Advertising Expenses | - | 104.31 | 132.54 | 84.83 | 44.26 |